Benjamin Speich1, Said M Ali2, Shaali M Ame2, Isaac I Bogoch3, Rainer Alles4, Jörg Huwyler4, Marco Albonico5, Jan Hattendorf6, Jürg Utzinger6, Jennifer Keiser7. 1. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and University of Basel, Basel, Switzerland. 2. Laboratory Division, Public Health Laboratory-Ivo de Carneri, Chake Chake, Tanzania. 3. Divisions of Internal Medicine and Infectious Diseases, Toronto General Hospital, Toronto, ON, Canada. 4. Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Basel, Switzerland. 5. Ivo de Carneri Foundation, Milan, Italy. 6. Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, and University of Basel, Basel, Switzerland. 7. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and University of Basel, Basel, Switzerland. Electronic address: jennifer.keiser@unibas.ch.
Abstract
BACKGROUND: Existing anthelmintic drugs (eg, albendazole and mebendazole) have low efficacy against the intestinal nematode species Trichuris trichiura and the drug pipeline is exhausted. We aimed to investigate the strategy of combination chemotherapy with existing drugs to establish whether their efficacy could be enhanced and broadened. METHODS: In this randomised controlled trial, we compared three drug combinations and one standard drug alone in children aged 6-14 years in two schools on Pemba Island, Tanzania infected with T trichiura and concomitant intestinal nematodes. We assigned children, via a randomisation list with block sizes of either four or eight, to orally receive albendazole (400 mg) plus ivermectin (200 μg/kg); albendazole (400 mg) plus mebendazole (500 mg); albendazole (400 mg) plus oxantel pamoate (20 mg/kg); or mebendazole (500 mg) alone. The primary endpoints were the proportion of children cured of T trichiura infection and the reduction of T trichiura eggs in stool based on geometric means, both analysed by available case. This study is registered with ISRCTN, number ISRCTN80245406. FINDINGS: We randomly assigned 440 eligible children infected with T trichiura between Sept 2, and Oct 18, 2013, to one of the four treatment groups (110 children per group). Data for 431 children were included in the analysis for the primary endpoints. Albendazole plus oxantel pamoate (74 of 108 children cured [68·5%, 95% CI 59·6-77·4]; egg reduction 99·2%, 98·7-99·6) and albendazole plus ivermectin (30 of 109 cured [27·5%, 19·0-36·0]; egg reduction 94·5%, 91·7-96·3) were significantly more effective against T trichiura than mebendazole alone (nine of 107 cured [8·4%, 3·1-13·8]; egg reduction 58·5%, 45·2-70·9). Albendazole plus mebendazole had similar low efficacy (nine of 107 cured [8·4%, 3·1-13·8; egg reduction 51·6%, 35·0-65·3) to mebendazole alone. About a fifth of the children reported adverse events, which were mainly mild. Abdominal cramps and headache were the most common adverse events after treatment; abdominal cramps were reported by 13 (12·0%) children for albendazole plus ivermectin, 10 (9·3%) for albendazole plus mebendazole, 20 (18·2%) for albendazole plus oxantel pamoate, and 16 (14·5%) for mebendazole; headaches were reported by 5 (4·6%) children for albendazole plus ivermectin, 6 (5·6%) for albendazole plus mebendazole, 12 (10·9%) for albendazole plus oxantel pamoate, and 7 (6·4%) for mebendazole. INTERPRETATION: Our head-to-head comparison of three combination chemotherapies showed the highest efficacy for albendazole plus oxantel pamoate for the treatment of infection with T trichiura. Further studies should investigate the combination of albendazole plus oxantel pamoate so that it can be considered for soil-transmitted helminthiasis control programmes. FUNDING: Medicor Foundation and Swiss National Science Foundation.
RCT Entities:
BACKGROUND: Existing anthelmintic drugs (eg, albendazole and mebendazole) have low efficacy against the intestinal nematode species Trichuris trichiura and the drug pipeline is exhausted. We aimed to investigate the strategy of combination chemotherapy with existing drugs to establish whether their efficacy could be enhanced and broadened. METHODS: In this randomised controlled trial, we compared three drug combinations and one standard drug alone in children aged 6-14 years in two schools on Pemba Island, Tanzania infected with T trichiura and concomitant intestinal nematodes. We assigned children, via a randomisation list with block sizes of either four or eight, to orally receive albendazole (400 mg) plus ivermectin (200 μg/kg); albendazole (400 mg) plus mebendazole (500 mg); albendazole (400 mg) plus oxantel pamoate (20 mg/kg); or mebendazole (500 mg) alone. The primary endpoints were the proportion of children cured of T trichiura infection and the reduction of T trichiura eggs in stool based on geometric means, both analysed by available case. This study is registered with ISRCTN, number ISRCTN80245406. FINDINGS: We randomly assigned 440 eligible children infected with T trichiura between Sept 2, and Oct 18, 2013, to one of the four treatment groups (110 children per group). Data for 431 children were included in the analysis for the primary endpoints. Albendazole plus oxantel pamoate (74 of 108 children cured [68·5%, 95% CI 59·6-77·4]; egg reduction 99·2%, 98·7-99·6) and albendazole plus ivermectin (30 of 109 cured [27·5%, 19·0-36·0]; egg reduction 94·5%, 91·7-96·3) were significantly more effective against T trichiura than mebendazole alone (nine of 107 cured [8·4%, 3·1-13·8]; egg reduction 58·5%, 45·2-70·9). Albendazole plus mebendazole had similar low efficacy (nine of 107 cured [8·4%, 3·1-13·8; egg reduction 51·6%, 35·0-65·3) to mebendazole alone. About a fifth of the children reported adverse events, which were mainly mild. Abdominal cramps and headache were the most common adverse events after treatment; abdominal cramps were reported by 13 (12·0%) children for albendazole plus ivermectin, 10 (9·3%) for albendazole plus mebendazole, 20 (18·2%) for albendazole plus oxantel pamoate, and 16 (14·5%) for mebendazole; headaches were reported by 5 (4·6%) children for albendazole plus ivermectin, 6 (5·6%) for albendazole plus mebendazole, 12 (10·9%) for albendazole plus oxantel pamoate, and 7 (6·4%) for mebendazole. INTERPRETATION: Our head-to-head comparison of three combination chemotherapies showed the highest efficacy for albendazole plus oxantel pamoate for the treatment of infection with T trichiura. Further studies should investigate the combination of albendazole plus oxantel pamoate so that it can be considered for soil-transmitted helminthiasis control programmes. FUNDING: Medicor Foundation and Swiss National Science Foundation.
Authors: Elora Valderas-García; Cécile Häberli; María Álvarez-Bardón; Nerea Escala; Verónica Castilla-Gómez de Agüero; Jennifer de la Vega; Esther Del Olmo; Rafael Balaña-Fouce; Jennifer Keiser; María Martínez-Valladares Journal: Parasit Vectors Date: 2022-07-08 Impact factor: 4.047
Authors: Beatrice Barda; Marco Albonico; Davide Ianniello; Shaali M Ame; Jennifer Keiser; Benjamin Speich; Laura Rinaldi; Giuseppe Cringoli; Roberto Burioni; Antonio Montresor; Jürg Utzinger Journal: PLoS Negl Trop Dis Date: 2015-04-07
Authors: Beatrice Barda; Marco Albonico; Dora Buonfrate; Shaali M Ame; Said Ali; Benjamin Speich; Jennifer Keiser Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: Benjamin Speich; Said M Ali; Shaali M Ame; Marco Albonico; Jürg Utzinger; Jennifer Keiser Journal: Parasit Vectors Date: 2015-02-05 Impact factor: 3.876
Authors: Hugo C Turner; James E Truscott; Alison A Bettis; T Déirdre Hollingsworth; Simon J Brooker; Roy M Anderson Journal: Parasite Epidemiol Control Date: 2016-06
Authors: Dora Buonfrate; Lorenzo Zammarchi; Zeno Bisoffi; Antonio Montresor; Sara Boccalini Journal: Infect Dis Poverty Date: 2021-05-25 Impact factor: 4.520
Authors: Benjamin Speich; Wendelin Moser; Said M Ali; Shaali M Ame; Marco Albonico; Jan Hattendorf; Jennifer Keiser Journal: Parasit Vectors Date: 2016-03-02 Impact factor: 3.876